Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

Vikingsstrade Oct. 3 at 7:29 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $IBKR $SNSE $RAPT $FGEN

0 · Reply

MoonCowBoy Oct. 3 at 12:34 AM

retail running ASTC now! the ASTC Float only 400k could squeeze hard wow $BNRG $IBKR $SNSE $RAPT "

0 · Reply

1Spartantrade1 Oct. 2 at 6:34 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $UNCY $BNRG $IBKR $SNSE 🚀

0 · Reply

MoonCowBoy Sep. 26 at 9:50 PM

retail running GYRO now! the GYRO Float only 600k could squeeze hard wow $SNSE $RAPT $SMX $UNCY (

0 · Reply

WallStVisions Sep. 24 at 11:15 AM

XPON - The lithium wave is real XPON is tied directly to it. Energy storage, home power, marine, RV all real-world growth verticals. Float is small. Chart is coiled. The next PR or volume burst could launch it. $NLST $SNSE $ACHL $BTTX $GLSI

0 · Reply

BullsEyePick Sep. 20 at 7:58 PM

$SEED $PHH $RNA $SNSE BOXL is the ticker to watch next week, It has that look. Shorts has been taking advantage of it and now with 0 shares to borrow, The squeeze is nearing. BOXL a must watch ticker in coming days!

0 · Reply

Punpire Sep. 19 at 2:27 PM

$DXCM Dexcom has some big problems moving forward. If they lose Endocrinologist they are going to be in big trouble. My Endo is impressed with my numbers after using the Eversense 365 the last 4 months. My A1C is almost Non Diabetic levels, it's currently Pre Diabetic at 5.8. $SNSE has such a golden opportunity to capitalize , I hope they figure out how to market and sell the 365. If you think the article from Hunterbrook is a hit piece I suggest you go read the comments from the Facebook group "Dexcom G7 Issues and Complaints".

2 · Reply

Robotai Sep. 17 at 2:13 AM

$SNSE 📈 Follow & Subscribe Swing Trading Forecast: $SNSE 📍 Current Price: $8.90 🔍 Swing Patterns: Major Upside Breakout, Major Upside Breakout, MACD Bearish Crossover 📊 Swing Market Structure: • Trend Regime: Neutral • Direction: Moderately Bullish (44.3% confidence) • Timeframe: 3-7 days 🎯 Moderately Bullish Swing Targets: • Conservative: $9.70 (+8.96%) • Primary Target: $10.23 (+14.93%) • Aggressive: $11.29 (+26.87%) • Holding Period: 3-7 days 📊 Technical Indicators: • ADX (Trend Strength): 6.9 • ATR (Volatility): $0.30 • RSI: 50.1 • MACD: Bearish 📈 Swing Signal Strength: 44.3% | Historical Patterns: 1

0 · Reply

NVDAMillionaire Sep. 10 at 12:02 PM

$SNSE Brilliant piece that captures SNSE's situation perfectly. So if you want to update your understanding of SNSE or get to know SNSE better, this is essential reading. https://beyondspx.com/quote/SNSE/analysis/sensei-biotherapeutics-a-high-stakes-bet-on-vista-in-the-oncology-arena-snse

0 · Reply

ibaian Aug. 22 at 4:57 AM

$SNSE $20 potential, low float pharma

0 · Reply

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 8 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 9 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 11 months ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 11 months ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 7, 2023, 5:15 PM EST - 2 years ago

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Mar 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 21, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Vikingsstrade Oct. 3 at 7:29 PM

0 · Reply

MoonCowBoy Oct. 3 at 12:34 AM

retail running ASTC now! the ASTC Float only 400k could squeeze hard wow $BNRG $IBKR $SNSE $RAPT "

0 · Reply

1Spartantrade1 Oct. 2 at 6:34 PM

0 · Reply

MoonCowBoy Sep. 26 at 9:50 PM

retail running GYRO now! the GYRO Float only 600k could squeeze hard wow $SNSE $RAPT $SMX $UNCY (

0 · Reply

WallStVisions Sep. 24 at 11:15 AM

0 · Reply

BullsEyePick Sep. 20 at 7:58 PM

0 · Reply

Punpire Sep. 19 at 2:27 PM

2 · Reply

Robotai Sep. 17 at 2:13 AM

0 · Reply

NVDAMillionaire Sep. 10 at 12:02 PM

0 · Reply

ibaian Aug. 22 at 4:57 AM

$SNSE $20 potential, low float pharma

0 · Reply

topstockalerts Aug. 15 at 5:28 PM

Top Gainers PT2 $MTNB $FOSL $XNET $UFG $SNSE

0 · Reply

littlestash Aug. 15 at 4:06 PM

$SNSE making moves

0 · Reply

GuyFawkes_EOD Aug. 15 at 1:39 PM

$SNSE halted 🤔

0 · Reply

Thunder000 Aug. 13 at 3:00 PM

$CGTX $HOTH $MIRA $SNSE Please consider come join $IBRX after you’ve done here. Great news and way way undervalued “ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy”

1 · Reply